- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective is to evaluate the safety and efficacy of the treatment with BAY 81-8973 for prophylaxis and treatment of breakthrough bleeds in children with haemophilia A
Critère d'inclusion
- Severe hemophilia A (< 1% FVIII:C)